(Guangzhou, China, August 31, 2022) Inside the ongoing Medical Fair Asia 2022, Pluslife Biotech has been showcasing its point-of-care molecular diagnostic system to the magnificent pavilion in the Marina Bay Sands, Singapore for the first time. The product presentation of Pluslife’s Mini Dock Molecular System is located in Booth No.2M05 until Sep 2. Pluslife is delighted to share the latest IVD technologies and deliver quality and affordable products to satisfy the rapidly expanding needs of rapid molecular POC instruments around the world.

According to the Foundation for Innovative New Diagnostics (FIND), the Next-Generation POC Molecular Diagnostic platform should possess the ability to be decentralized in the entire healthcare system with multiple target detection. The palm-sized Pluslife Mini Dock molecular system meets the FIND standards by featuring no constraints in settings while detecting multiple pathogens in single test cards, for instance, the COVID-19/Influenza A&B combo test, the CT/NG/UU combo test, the Feline FCM combo test and others.

As one of the world's pioneers in rapid POC molecular systems, Pluslife has been making significant contributions to the COVID-19 pandemic prevention and control. Being a nucleic acid test that differs from the qPCR test, testing through the Pluslife Mini Dock Molecular System could be completed on-site with a simple testing procedure and short TAT within 35 minutes while maintaining comparable results to qPCR tests. Most importantly, applying Pluslife’s products in an epidemical context like COVID-19 could mitigate the healthcare system challenge when it is short of well-trained medical personnel and overloaded by the extensive testing volume. Alerted by the rising number of monkeypox infections in the world, the Pluslife team is adding the monkeypox testing card to its product menu in meeting the diagnostic need of global healthcare authorities.

Congratulations to Pluslife’s first-ever demonstration in the Medical Fair Asia exhibition. Pluslife is excited to be able to showcase its top-standard molecular diagnostics to visitors around the globe and, will continue to fulfill its promise of making rapid molecular tests more accessible to all.